Mesenchymal Stem/Stromal Cells for Therapeutic Angiogenesis

Cells. 2023 Aug 28;12(17):2162. doi: 10.3390/cells12172162.

Abstract

Mesenchymal stem/stromal cells (MSCs) are known to possess medicinal properties to facilitate vascular regeneration. Recent advances in the understanding of the utilities of MSCs in physiological/pathological tissue repair and technologies in isolation, expansion, and enhancement strategies have led to the use of MSCs for vascular disease-related treatments. Various conditions, including chronic arterial occlusive disease, diabetic ulcers, and chronic wounds, cause significant morbidity in patients. Therapeutic angiogenesis by cell therapy has led to the possibilities of treatment options in promoting angiogenesis, treating chronic wounds, and improving amputation-free survival. Current perspectives on the options for the use of MSCs for therapeutic angiogenesis in vascular research and in medicine, either as a monotherapy or in combination with conventional interventions, for treating patients with peripheral artery diseases are discussed in this review.

Keywords: critical limb ischemia; mesenchymal stem/stromal cells; therapeutic angiogenesis.

Publication types

  • Review

MeSH terms

  • Amputation, Surgical
  • Cell- and Tissue-Based Therapy
  • Humans
  • Medicine*
  • Mesenchymal Stem Cells*
  • Peripheral Arterial Disease*

Grants and funding

This research received no external funding.